Title of article :
Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus
Author/Authors :
David R. Jones MD، نويسنده , , Frank C. Detterbeck MD، نويسنده , , Thomas M. Egan MD، نويسنده , , Leonard A. Parker Jr MD، نويسنده , , Stephen A. Bernard MD، نويسنده , , Joel E. Tepper MD، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 1997
Abstract :
Background. Induction chemoradiotherapy followed by esophagectomy may provide results superior to those of single-modality treatment in patients with esophageal cancer. The purpose of this study was to review our experience with this approach for esophageal cancer.
Methods. From 1988 to 1996, 166 consecutive patients with esophageal cancer were evaluated; 66 entered a protocol of chemotherapy (5-fluorouracil, cisplatin) concurrent with radiation (45 Gy) followed by esophagectomy. Fifty-four patients completed the protocol.
Results. Toxicity associated with induction chemoradiotherapy was minimal. The actuarial survival at 12, 24, and 36 months was 59%, 42%, and 32%, respectively. The pathologic complete response (pCR) rate was 41%, with 12-, 24-, and 36-month survivals of 77%, 50%, and 45%, whereas non-pCR patients had survivals of 46%, 35%, and 23%. The difference in survival between pCR and non-pCR patients was not significant (p = 0.13), but the difference in recurrence-free survival was significant (p = 0.007).
Conclusions. This well-tolerated protocol resulted in a high pCR. Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status.
Journal title :
The Annals of Thoracic Surgery
Journal title :
The Annals of Thoracic Surgery